657 results match your criteria Sarcoma [Journal]


A Cadaveric Comparative Study on the Surgical Accuracy of Freehand, Computer Navigation, and Patient-Specific Instruments in Joint-Preserving Bone Tumor Resections.

Sarcoma 2018 13;2018:4065846. Epub 2018 Nov 13.

Department of Orthopedics, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, Netherlands.

Orthopedic oncologic surgery requires preservation of a functioning limb at the essence of achieving safe margins. With most bone sarcomas arising from the metaphyseal region, in close proximity to joints, joint-salvage surgery can be challenging. Intraoperative guidance techniques like computer-assisted surgery (CAS) and patient-specific instrumentation (PSI) could assist in achieving higher surgical accuracy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/4065846DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6260549PMC
November 2018
1 Read

Adult Primary Bone Sarcoma and Time to Treatment Initiation: An Analysis of the National Cancer Database.

Sarcoma 2018 11;2018:1728302. Epub 2018 Nov 11.

Orthopaedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

Objective: The time to treatment interval (TTI), defined as the period from diagnosis to first definitive treatment, has very limited descriptions toward understanding delays in primary bone sarcoma (PBS) care. Our primary goal was to determine the national standard for time to treatment initiation (TTI) in PBS in adults and to identify characteristics associated with TTI variability.

Methods: An analysis of the National Cancer Database identified 15,083 adult patients with PBS diagnosed from 2004 to 2013. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/1728302DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252187PMC
November 2018

Myxoid Liposarcoma: Treatment Outcomes from Chemotherapy and Radiation Therapy.

Sarcoma 2018 1;2018:8029157. Epub 2018 Nov 1.

Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.

Introduction: Myxoid liposarcoma (MLS) is a subtype of liposarcoma characterized morphologically by lipomatous differentiation with a myxoid stroma. The purpose of this study was to review clinical and pathological information for patients treated for MLS at our institution to better understand neoadjuvant and adjuvant therapy.

Materials And Methods: An institutional database of sarcomas was queried for patients who were treated for MLS at our institution between 1992 and 2013. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/sarcoma/2018/8029157/
Publisher Site
http://dx.doi.org/10.1155/2018/8029157DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236966PMC
November 2018
4 Reads

SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy.

Sarcoma 2018 24;2018:2068517. Epub 2018 Oct 24.

MD Anderson Cancer Center, Sarcoma Medical Oncology, 1400 Holcombe Blvd, Unit 450, Houston, TX 77030, USA.

Histone deacetylase inhibitors (HDACi) can reverse chemoresistance, enhance chemotherapy-induced cytotoxicity, and reduce sarcoma proliferation in cell lines and animal models. We sought to determine the safety and toxicity of mocetinostat and its ability to reverse chemoresistance when administered with gemcitabine in patients with metastatic leiomyosarcoma resistant to prior gemcitabine-containing therapy. Participants with metastatic leiomyosarcoma received mocetinostat orally, 70 mg per day, three days per week, increasing to 90 mg after three weeks if well tolerated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/2068517DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220374PMC
October 2018
2 Reads

Periosteal Osteosarcoma: A Single-Institutional Study of Factors Related to Oncologic Outcomes.

Sarcoma 2018 27;2018:8631237. Epub 2018 Sep 27.

Division of Orthopaedic Oncology, Department of Orthopaedics and Rehabilitation, University of Florida, Gainesville, FL, USA.

Background: Periosteal osteosarcoma is a rare surface-based variant with a lower propensity to metastasis and better prognosis than conventional osteosarcoma. The literature supporting survival benefit with adjuvant chemotherapy is lacking. Our institutional practice is for chemotherapy to be offered to patients with high-grade disease. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/sarcoma/2018/8631237/
Publisher Site
http://dx.doi.org/10.1155/2018/8631237DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180962PMC
September 2018
5 Reads

Health Care Resource Utilization and Costs among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France.

Sarcoma 2018 12;2018:2020591. Epub 2018 Sep 12.

Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK.

Objective: To describe health care resource utilization and costs for patients with advanced soft tissue sarcoma (STS) in the United Kingdom (UK), Spain, Germany, and France.

Methods: Physicians abstracted data for adult patients with a diagnosis of advanced STS (other than Kaposi's sarcoma or gastrointestinal stromal tumor) who received ≥1 lines of systemic therapy. Health care resource utilization related to advanced STS treatment was recorded; associated costs were estimated by applying unit costs. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/sarcoma/2018/2020591/
Publisher Site
http://dx.doi.org/10.1155/2018/2020591DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157208PMC
September 2018
1 Read

Benign Smooth Muscle Tumors (Leiomyomas) of Deep Somatic Soft Tissue.

Sarcoma 2018 9;2018:2071394. Epub 2018 Sep 9.

Department of Anatomical Pathology, Laboratory Medicine Program, University Health Network and University of Toronto, Toronto, ON, Canada.

Leiomyomas of deep soft tissue are extremely rare and should only be diagnosed following adherence to stringent histological criteria, namely, the absence of nuclear atypia and of coagulative tumor necrosis. Whether extremely low counts of, or even any, mitotic activity are acceptable when making a diagnosis of leiomyoma in deep soft tissue sites is controversial. The morphology and immunophenotype of smooth muscle tumors in deep soft tissue are similar to their counterparts irrespective of topography. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/sarcoma/2018/2071394/
Publisher Site
http://dx.doi.org/10.1155/2018/2071394DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151232PMC
September 2018
2 Reads

Addressing the Adult Soft Tissue Sarcoma Microenvironment with Intratumoral Immunotherapy.

Sarcoma 2018 12;2018:9305294. Epub 2018 Aug 12.

Wake Forest School of Medicine, Winston-Salem, NC, USA.

Sarcoma is comprised of a heterogeneous group of tumors originating from the mesenchyme. Sarcoma is also the first tumor that responded to immunotherapeutic agents often termed as "Coley's toxins." However, immunotherapy is yet to establish its presence in sarcomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/9305294DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109466PMC

Comparison of Epidemiology, Clinical Features, and Outcomes of Patients with Reported Ewing Sarcoma and PNET over 40 Years Justifies Current WHO Classification and Treatment Approaches.

Sarcoma 2018 8;2018:1712964. Epub 2018 Aug 8.

Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA, USA.

Background: As of 2013, the WHO has classified peripheral primitive neuroectodermal tumors (PNETs) within the umbrella of Ewing sarcoma family of tumors (ESFTs) given their shared biology. Histologic features differ between PNET and Ewing sarcoma (ES), and potential clinical differences between PNET and ES have not been fully elucidated.

Methods: Through the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database, we identified 3,575 patients identified with histologic diagnosis of ES or PNET from 1973 to 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/1712964DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109476PMC

The Volume-Outcome Relationship in Retroperitoneal Soft Tissue Sarcoma: Evidence of Improved Short- and Long-Term Outcomes at High-Volume Institutions.

Sarcoma 2018 24;2018:3056562. Epub 2018 Jul 24.

Department of Surgery, Section of Surgical Oncology, Mayo Clinic, Phoenix, AZ, USA.

Background: We sought to study the association between RPS case volume and outcomes. Although a relationship has been demonstrated between case volume and patient outcomes in some cancers, such a relationship has not been established for retroperitoneal sarcomas (RPSs).

Study Design: The National Cancer Database (NCDB) was queried for patients undergoing treatment for primary RPS diagnosed between 2004 and 2013. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/3056562DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081523PMC
July 2018
1 Read

A Longitudinal Study of Functional Outcomes in Patients with Limb Salvage Surgery for Soft Tissue Sarcoma.

Sarcoma 2018 12;2018:6846275. Epub 2018 Apr 12.

Department of Orthopedic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Ilwon-Ro, Gangnam-gu, Seoul 06351, Republic of Korea.

Background: Many studies have reported on the surgical outcomes of soft tissue sarcoma. However, there was no longitudinal cohort study. Because time is the most valuable factor for functional recovery, adjusting time value was the key for finding the causal relationship between other risk factors and postoperative function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/6846275DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079357PMC
April 2018
7 Reads

Outcome of Nonsurgical Management of Extra-Abdominal, Trunk, and Abdominal Wall Desmoid-Type Fibromatosis: A Population-Based Study in the Netherlands.

Sarcoma 2018 21;2018:5982575. Epub 2018 Jun 21.

Department of Medical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, P.O. Box 90203, 1006 BE Amsterdam, Netherlands.

Introduction: Nonsurgical management of patients with desmoid-type fibromatosis (DF) is increasing. This study tries to provide insight on type, usage, and outcome of first-line nonsurgical management strategies.

Patients And Methods: From the Dutch Pathology Registry (PALGA), patients with extra-abdominal or trunk/abdominal wall DF, diagnosed between 1993 and 2013, were identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/5982575DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032644PMC
June 2018
1 Read

Safety and Accuracy of Core Needle Biopsy for Soft Tissue Masses in an Ambulatory Setting.

Sarcoma 2018 12;2018:1657864. Epub 2018 Jun 12.

University of Arizona College of Medicine, Phoenix, AZ, USA.

Background: Percutaneous needle biopsy has been found to be a safe and accurate method for the initial investigation of soft tissue masses. The notion exists that needle biopsies should be performed in specialized sarcoma centers, which can place a financial burden on patients without a sarcoma center near their place of residence. There is no consensus in the current literature regarding the diagnostic accuracy and clinical utility of clinic-based percutaneous core needle biopsy performed by community orthopedic surgeons with fellowship training in musculoskeletal oncology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/1657864DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6020496PMC

Treatment Patterns and Survival among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France.

Sarcoma 2018 24;2018:5467057. Epub 2018 May 24.

RTI Health Solutions, 200 Park Offices Drive, Research Triangle Park, Durham, NC 27709, USA.

Objective: To describe real-world treatment patterns and outcomes for patients with advanced soft tissue sarcoma (STS) not amenable to surgery or radiotherapy in the United Kingdom, Spain, Germany, and France.

Methods: Physicians completed a web-based medical record abstraction for adult patients with advanced STS (other than Kaposi's sarcoma or gastrointestinal stromal tumor) who received ≥1 line of systemic therapy. Clinical characteristics, treatments, tumor responses, and mortality data were recorded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/5467057DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5994280PMC
May 2018
6 Reads

Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for Children and Young Adults with Relapsed Ewing's Sarcoma: A Systematic Review.

Sarcoma 2018 3;2018:2640674. Epub 2018 Jun 3.

Division of Hematology and Oncology, Department of Medicine, University of Arizona, Tucson, AZ 85721, USA.

Background: Relapsed Ewing's sarcoma (RES) is an aggressive malignancy with poor survival. Although high-dose chemotherapy (HDCT) with autologous stem cell transplantation (ASCT) given after conventional chemotherapy (CC) has shown survival benefits, it is not generally used in the United States for RES. We performed a systemic review to evaluate the benefits of HDCT for RES. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/2640674DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008812PMC
June 2018
8 Reads

Sister Chromatid Exchange and Genomic Instability in Soft Tissue Sarcomas: Potential Implications for Response to DNA-Damaging Treatments.

Sarcoma 2018 7;2018:3082526. Epub 2018 May 7.

Medical School, University of Sheffield, Sheffield, UK.

Sarcomas are rare heterogeneous malignancies of mesenchymal origin characterised by complex karyotypes but no specific abnormalities. Recurrence is common, and metastatic disease carries poor survival despite standard DNA-damaging radiotherapy or chemotherapy. DNA double-strand breaks (DSBs) are either repaired by mechanisms such as homologous recombination (HR) or result in cell death by apoptosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/3082526DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964616PMC
May 2018
4 Reads

High-Dose Chemotherapy with Stem Cell Rescue in Desmoplastic Small Round Cell Tumor: A Single-Institution Experience and Review of the Literature.

Sarcoma 2018 6;2018:1948093. Epub 2018 May 6.

Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Purpose: Desmoplastic small round cell tumor (DSRCT) is a rare cancer that predominantly affects males averaging 21 years of age at the time of diagnosis. We describe four cases from our institution and place them within the context of a comprehensive review of the literature.

Patients And Methods: Study population included any patient who received treatment at Children's Hospital at Montefiore (CHAM) with histologic diagnosis of DSRCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/1948093DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960572PMC

High-Grade Osteosarcoma of the Foot: Presentation, Treatment, Prognostic Factors, and Outcome of 23 Cooperative Osteosarcoma Study Group COSS Patients.

Sarcoma 2018 2;2018:1632978. Epub 2018 May 2.

Center for Pediatric, Adolescent and Women's Medicine, Olgahospital, Department of Pediatrics 5 (Oncology, Hematology, Immunology), Klinikum Stuttgart, Stuttgart, Germany.

Osteosarcoma of the foot is a very rare presentation of a rare tumor entity. In a retrospective analysis, we investigated tumor- and treatment-related variables and outcome of patients registered in the Cooperative Osteosarcoma Study Group (COSS) database between January 1980 and April 2016 who suffered from primary high-grade osteosarcoma of the foot. Among the 23 eligible patients, median age was 32 years (range: 6-58 years), 10 were female, and 13 were male. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/sarcoma/2018/1632978/
Publisher Site
http://dx.doi.org/10.1155/2018/1632978DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954899PMC
May 2018
5 Reads

Outcome for Advanced or Metastatic Soft Tissue Sarcoma of Nonextremities Treated with Doxorubicin-Based Chemotherapy: A Retrospective Study from a Single Cancer Institution.

Sarcoma 2018 18;2018:8926598. Epub 2018 Apr 18.

Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.

Background: Doxorubicin is the key drug for treatment of advanced soft tissue sarcoma (STS). The appropriate dosage of doxorubicin, regarding monotherapy or the role of combination therapy, is unclear.

Methods: We retrospectively reviewed patients with advanced or metastatic STS of nonextremities who were treated with doxorubicin-based chemotherapies in our institution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/8926598DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932429PMC

Improving Long-Term Outcomes for Patients with Extra-Abdominal Soft Tissue Sarcoma Regionalization to High-Volume Centers, Improved Compliance with Guidelines or Both?

Sarcoma 2018 3;2018:8141056. Epub 2018 Apr 3.

Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Surgical Outcomes Division, Mayo Clinic Arizona, Phoenix, AZ, USA.

Introduction: Optimization of outcomes of extra-abdominal STS is not clearly understood. We sought to determine whether hospital surgical volume and adherence to NCCN guidelines, or both, are associated with outcomes in the treatment of extra-abdominal soft tissue sarcoma (STS).

Methods: The National Cancer Database (NCDB) was queried for patients undergoing surgery for extra-abdominal STS diagnosed from 2003 to 2007. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/8141056DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903348PMC
April 2018
1 Read

Epidemiology of Adult Soft-Tissue Sarcomas in Germany.

Sarcoma 2018 4;2018:5671926. Epub 2018 Apr 4.

RTI Health Solutions, 307 Waverly Oaks Rd., Suite 101, Waltham, MA, USA.

We conducted a retrospective cohort study using data compiled from the regional German cancer registries by the Centre for Cancer Registry Data (ZfKD) at the Robert Koch Institut (RKI) to describe the epidemiology of adult soft-tissue sarcomas (STS) in Germany in 2003-2012, focusing on advanced STS. We identified 33,803 incident adult cases of STS (other than the Kaposi sarcoma and gastrointestinal stromal tumors). The incidence of STS was 6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/5671926DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5904765PMC
April 2018
2 Reads

Treatment of Sarcoma Lung Metastases with Stereotactic Body Radiotherapy.

Sarcoma 2018 1;2018:9132359. Epub 2018 Apr 1.

Department of Orthopaedic Surgery, University of Florida, Gainesville, FL, USA.

Background: The most common site of sarcoma metastasis is the lung. Surgical resection of pulmonary metastases and chemotherapy are treatment options that have been employed, but many patients are poor candidates for these treatments for multiple host or tumor-related reasons. In this group of patients, radiation might provide a less morbid treatment alternative. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/sarcoma/2018/9132359/
Publisher Site
http://dx.doi.org/10.1155/2018/9132359DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901828PMC
April 2018
7 Reads

Multiple Soft Tissue Sarcomas in a Single Patient: An International Multicentre Review.

Sarcoma 2018 1;2018:5392785. Epub 2018 Apr 1.

McGill University Health Centre, Montreal, QC, Canada H4A 3J1.

Developing multiple soft tissue sarcomas (STSs) is a rare process, sparsely reported in the literature to date. Little is known about the pattern of disease development or outcomes in these patients. Patients were identified from three tertiary orthopaedic oncology centres in Canada and the UK. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/5392785DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901826PMC
April 2018
3 Reads

Retrospective Analysis of Spectrum of Presentation and Treatment Outcome in Extremity Sarcomas: A Single-Centre Experience.

Sarcoma 2018 1;2018:4350634. Epub 2018 Apr 1.

Department of Surgical Oncology, Cancer Research Institute, SRHU, Dehradun, Uttarakhand, India.

Introduction: The most common site for soft tissue sarcoma is extremity. As complete surgical resection is possible in majority, outcome of this subset is relatively better. There is paucity of data regarding extremity soft tissue sarcoma (STS) from sub-Himalayan and hilly geographical regions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/4350634DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901834PMC
April 2018
6 Reads

Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States.

Sarcoma 2018 26;2018:6703963. Epub 2018 Mar 26.

Eli Lilly and Company Limited, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK.

Background: Standard first-line treatments for advanced soft tissue sarcoma (STS) have changed little for 40 years, and outcomes have been poor. Recently, the United States (US) Food and Drug Administration conditionally approved olaratumab in combination with doxorubicin (Olara + Dox) based on a randomized phase II trial that reported a significant 11.8-month improvement in median survival versus single-agent doxorubicin (Dox). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/6703963DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892240PMC

The Value of MRI in Distinguishing Subtypes of Lipomatous Extremity Tumors Needs Reassessment in the Era of MDM2 and CDK4 Testing.

Sarcoma 2018 19;2018:1901896. Epub 2018 Mar 19.

Duke University Hospital, 2301 Erwin Rd., Durham, NC 27710, USA.

Introduction: Extremity lipomas and well-differentiated liposarcomas (WDLs) are difficult to distinguish on MR imaging. We sought to evaluate the accuracy of MRI interpretation using MDM2 amplification, via fluorescence in-situ hybridization (FISH), as the gold standard for pathologic diagnosis. Furthermore, we aimed to investigate the utility of a diagnostic formula proposed in the literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/1901896DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884200PMC

Impact of Insurance Coverage on Outcomes in Primary Breast Sarcoma.

Sarcoma 2018 15;2018:4626174. Epub 2018 Mar 15.

Department of Radiation Oncology, Stanford University Medical Center, 875 Blake Wilbur Drive, Stanford, CA 94305-5847, USA.

Private insurance is associated with better outcomes in multiple common cancers. We hypothesized that insurance status would significantly impact outcomes in primary breast sarcoma (PBS) due to the additional challenges of diagnosing and coordinating specialized care for a rare cancer. Using the National Cancer Database, we identified adult females diagnosed with PBS between 2004 and 2013. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/4626174DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875066PMC
March 2018
1 Read

Limb-Salvage Surgery of Soft Tissue Sarcoma with Sciatic Nerve Involvement.

Sarcoma 2018 6;2018:6483579. Epub 2018 Mar 6.

Department of Surgery, Clinical Center Frankfurt Höchst, Frankfurt, Germany.

Background: The surgical resection of soft tissue sarcomas (STS) with sciatic nerve involvement presents a significant surgical and oncological challenge. Current treatment strategies pursue a multimodal approach with the aim of limb preservation. We aim to evaluate the outcomes of limb-sparing surgery of STS in a patient cohort and to propose a classification for STS with sciatic nerve involvement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/6483579DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859890PMC
March 2018
2 Reads

Correlation of High-Risk Soft Tissue Sarcoma Biomarker Expression Patterns with Outcome following Neoadjuvant Chemoradiation.

Sarcoma 2018 28;2018:8310950. Epub 2018 Feb 28.

Duke University Medical Center, Durham, NC, USA.

Background: Sarcoma mortality remains high despite adjuvant chemotherapy. Biomarker predictors of treatment response and outcome could improve treatment selection.

Methods: Tissue microarrays (TMAs) were created using pre- and posttreatment tumor from two prospective trials (MGH pilot and RTOG 9514) of neoadjuvant/adjuvant MAID chemotherapy and preoperative radiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/8310950DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851029PMC
February 2018
2 Reads

When Do Orthopaedic Oncologists Consider the Implantation of Expandable Prostheses in Bone Sarcoma Patients?

Sarcoma 2018 25;2018:3504075. Epub 2018 Feb 25.

Department of Orthopaedic Surgery and Traumatology, Medical University of Graz, Graz, Austria.

Introduction: Indications discussed for the implantation of expandable prostheses in bone sarcoma patients are unclear. This survey aimed to analyse common practice with this implant type in orthopaedic oncology.

Methods: A web-based survey was sent to 98 orthopaedic oncology surgeons. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/3504075DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845529PMC
February 2018

Aerosol Gemcitabine after Amputation Inhibits Osteosarcoma Lung Metastases but Not Wound Healing.

Sarcoma 2018 21;2018:3143096. Epub 2018 Jan 21.

The University of Texas MD Anderson Cancer Center, Division of Pediatrics, 1515 Holcombe Blvd., Unit 0853, Houston, TX 77030, USA.

Background: In newly diagnosed osteosarcoma (OS) patients, the time between surgery and resumption of chemotherapy is 2-7 weeks. Delays > 16 days are associated with increased risk of relapse and decreased overall survival. Identifying an effective therapy that can be used postoperatively may prevent relapse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/3143096DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828535PMC
January 2018
1 Read

Treatment of Recurrent or Metastatic Uterine Adenosarcoma.

Sarcoma 2017 28;2017:4680273. Epub 2017 Dec 28.

Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Unit 450, Houston, TX 77030, USA.

Purpose: This study retrospectively evaluated overall survival (OS) by treatment of recurrent or metastatic uterine adenosarcoma including surgery, radiation, chemotherapy, and hormonal therapy and evaluated OS and progression-free survival (PFS) after 1st line systemic chemotherapy.

Methods: 78 patients with recurrent or metastatic adenosarcoma comprised the study population. The Kaplan-Meier method was used to estimate OS and PFS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/4680273DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763139PMC
December 2017
2 Reads

Ovary-Sparing Radiation Planning Techniques Can Achieve Ovarian Dose Reduction for Soft Tissue Sarcoma of the Buttock and Thigh.

Sarcoma 2017 18;2017:2796925. Epub 2017 Sep 18.

Department of Radiation Oncology, Brigham and Women's Hospital/Dana Farber Cancer Institute, Boston, MA, USA.

Background And Objectives: Attention to ovary dose is important for premenopausal women undergoing radiation therapy (RT) and must not be overlooked when treating extremity sarcoma. We assessed whether ovary-sparing RT plans could decrease ovary dose without compromising target coverage.

Methods: Standard sarcoma target volumes and organs at risk (OAR) were contoured by a sarcoma dedicated radiation oncologist on CT planning scans for 23 women with thigh or buttock sarcoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/2796925DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624159PMC
September 2017
9 Reads

Desmoplastic Small Round Blue Cell Tumor: A Review of Treatment and Potential Therapeutic Genomic Alterations.

Sarcoma 2017 1;2017:1278268. Epub 2017 Nov 1.

Department of Pediatric Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Desmoplastic small round blue cell tumors (DSRCTs) originate from a cell with multilineage potential. A molecular hallmark of DSRCT is the EWS-WT1 reciprocal translocation. Ewing sarcoma and DSRCT are treated similarly due to similar oncogene activation pathways, and DSRCT has been represented in very limited numbers in sarcoma studies. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/sarcoma/2017/1278268/
Publisher Site
http://dx.doi.org/10.1155/2017/1278268DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687144PMC
November 2017
8 Reads

SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors.

Sarcoma 2017 12;2017:8685638. Epub 2017 Sep 12.

Pediatric Oncology Branch, NCI, CCR, Bethesda, MD, USA.

Background: Worse chemotherapy response for neurofibromatosis type 1- (NF1-) associated compared to sporadic malignant peripheral nerve sheath tumors (MPNST) has been reported.

Methods: We evaluated the objective response (OR) rate of patients with AJCC Stage III/IV chemotherapy-naive NF1 MPNST versus sporadic MPNST after 4 cycles of neoadjuvant chemotherapy, 2 cycles of ifosfamide/doxorubicin, and 2 cycles of ifosfamide/etoposide. A Simon optimal two-stage design was used (target response rate 40%). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/8685638DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613633PMC
September 2017
21 Reads

Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion.

Sarcoma 2017 26;2017:7495914. Epub 2017 Sep 26.

Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 450, Houston, TX 77030, USA.

Background: Despite the dose-dependent response rate of sarcomas to doxorubicin, clinicians limit its cumulative dose due to cardiotoxicity. This study evaluates early evidence of cardiotoxicity in patients treated with high-dose doxorubicin given as a continuous infusion.

Methods: Data was collected on patients who received 90 mg/m doxorubicin as a continuous infusion and 10 gm/m ifosfamide for up to 6 cycles as part of a phase II study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/7495914DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634608PMC
September 2017
16 Reads

High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma.

Sarcoma 2017 30;2017:3739159. Epub 2017 Aug 30.

Medical Oncology Unit 2, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Background: To report on the activity of high-dose prolonged-infusion ifosfamide (HDIFX) chemotherapy in a retrospective series of patients affected by myxoid liposarcoma treated at Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy.

Patients And Methods: Patients with an advanced myxoid liposarcoma treated with HDIFX (14 g/sqm, i.v. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/3739159DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602616PMC
August 2017
10 Reads

Multimodal Approach of Pulmonary Artery Intimal Sarcoma: A Single-Institution Experience.

Sarcoma 2017 20;2017:7941432. Epub 2017 Aug 20.

Cardiothoracic Surgery Department, Fondazione IRCCS Policlinico San Matteo and Pavia University School of Medicine, Pavia, Italy.

Introduction: Pulmonary artery sarcoma (PAS) is a rare tumor, whose therapeutic approach is mainly based on surgery, either pneumonectomy or pulmonary endarterectomy (PEA). The prognosis reported in published series is very poor, with survival of 1.5 months without any kind of treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/7941432DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5585613PMC
August 2017
1 Read

Cross-Cultural Adaptation, Translation, and Validation of the Toronto Extremity Salvage Score for Extremity Bone and Soft Tissue Tumor Patients in Netherlands.

Sarcoma 2017 20;2017:6197525. Epub 2017 Jul 20.

Department of Orthopaedic Surgery, Leiden University Medical Center, Leiden, Netherlands.

Purpose: The aim of this study was to translate and culturally adapt the Toronto Extremity Salvage Score (TESS) to Dutch and to validate the translated version.

Methods: The TESS lower and upper extremity versions (LE and UE) were translated to Dutch according to international guidelines. The translated version was validated in 98 patients with surgically treated bone or soft tissue tumors of the LE or UE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/6197525DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5541809PMC
July 2017
3 Reads

Preoperative Factors Associated with Infiltrative Histologic Growth Patterns in Extremity Soft Tissue Sarcoma.

Sarcoma 2017 20;2017:5419394. Epub 2017 Jul 20.

Department of Orthopaedic Surgery, Seoul National University Hospital, Seoul, Republic of Korea.

Soft tissue sarcoma (STS) with an infiltrative histologic growth pattern, when compared to STS with an expansile pattern, may pose difficulties in local control. Preoperative assessment of the presence of infiltrative histologic growth pattern would be helpful in deciding treatment strategies. A review of 144 patients who underwent surgery for extremity STS was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/5419394DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5541793PMC
July 2017
8 Reads

Concurrent Imatinib and Radiation Therapy for Unresectable and Symptomatic Desmoid Tumors.

Sarcoma 2017 5;2017:2316839. Epub 2017 Jul 5.

Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA.

Desmoid tumors are locally aggressive fibroproliferative neoplasms that can lead to pain and dysfunction due to compression of nerves and surrounding structures. Desmoid tumors often progress through medical therapy, and there is frequently a delay of multiple months before radiation can provide symptomatic relief. To achieve more rapid symptomatic relief and tumor regression for unresectable desmoid tumors causing significant morbidity such as brachial plexus impingement with loss of extremity function, we have selectively utilized a combination of imatinib and radiation therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/2316839DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516706PMC
July 2017
4 Reads

Predictors of Wound Complications following Radiation and Surgical Resection of Soft Tissue Sarcomas.

Sarcoma 2017 15;2017:5465130. Epub 2017 Jun 15.

Department of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Boulevard, 10-179 South Pavilion, Philadelphia, PA 19104, USA.

Wound complications represent a major source of morbidity in patients undergoing radiation therapy (RT) and surgical resection of soft tissue sarcomas (STS). We investigated whether factors related to RT, surgery, patient comorbidities, and tumor histopathology predict the development of wound complications. An observational study of patients who underwent STS resection and RT was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/5465130DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494566PMC
June 2017
1 Read

Pasteurized Autograft-Prosthesis Composite Reconstruction May Not Be a Viable Primary Procedure for Large Skeletal Defects after Resection of Sarcoma.

Sarcoma 2017 4;2017:9710964. Epub 2017 Jun 4.

Department of Orthopedic Surgery, Korea Cancer Center Hospital, Seoul, Republic of Korea.

Background: Among various types of composite biological reconstruction, pasteurized autograft-prosthesis composite (PPC) is popular when allograft is unavailable. Previous limited cohort study indicated result comparable to tumor prosthesis. However, as case number and follow-up increase, we experienced more complications than anticipated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/9710964DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474264PMC
June 2017
16 Reads

Synovial Sarcoma of the Head and Neck: A Single Institution Review.

Sarcoma 2017 5;2017:2016752. Epub 2017 Jun 5.

Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.

Background: The prognosis and clinical characteristics of head and neck synovial sarcomas (HNSS) are unclear. Herein, we present an update using a cohort of patients treated at our institution.

Methods: We performed a retrospective chart review of 44 patients diagnosed with primary HNSS between March 1990 and June 2012. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/2016752DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474548PMC
June 2017
12 Reads

Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies.

Sarcoma 2017 16;2017:7429697. Epub 2017 May 16.

National Cancer Institute, Pediatric Oncology Branch, 10 Center Drive, Room 1-3742, Building 10, Bethesda, MD 20892, USA.

Malignant peripheral nerve sheath tumor (MPNST) is the leading cause of mortality in patients with neurofibromatosis type 1. In 2002, an MPNST consensus statement reviewed the current knowledge and provided guidance for the diagnosis and management of MPNST. Although the improvement in clinical outcome has not changed, substantial progress has been made in understanding the natural history and biology of MPNST through imaging and genomic advances since 2002. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/7429697DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448069PMC
May 2017
12 Reads

Results of a Qualitative Study to Develop a Patient Reported Outcome Measure for Patients with 4 Subtypes of Soft Tissue Sarcoma.

Sarcoma 2017 14;2017:6868030. Epub 2017 May 14.

Evidera, Bethesda, MD, USA.

Objective: The objective of this research was to develop a disease-specific symptom inventory for soft tissue sarcoma.

Methods: Literature review and clinical expert and patient interviews were conducted to determine disease-specific symptoms important to patients with one of the four STS subtypes. Clinical experts identified the most relevant STS symptom items from the item pool developed from literature review. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/6868030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446879PMC
May 2017
21 Reads

Neoadjuvant Ifosfamide and Epirubicin in the Treatment of Malignant Peripheral Nerve Sheath Tumors.

Sarcoma 2017 4;2017:3761292. Epub 2017 May 4.

Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, 660 South Euclid Ave., St. Louis, MO 63110, USA.

Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas with poor overall survival. Response to chemotherapy has been debated for these tumors. We performed a retrospective analysis of the patients at our institution with a biopsy-proven diagnosis of MPNST that underwent neoadjuvant chemotherapy prior to surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/3761292DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5435903PMC
May 2017
6 Reads

Evaluation of Quality of Life at Progression in Patients with Soft Tissue Sarcoma.

Sarcoma 2017 23;2017:2372135. Epub 2017 Apr 23.

Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands.

. Soft Tissue Sarcoma (STS) is a rare malignancy of mesodermal tissue, with international incidence estimates between 1.8 and 5 per 100,000 per year. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/2372135DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5420413PMC
April 2017
19 Reads

Variations of Surveillance Practice for Patients with Bone Sarcoma: A Survey of Australian Sarcoma Clinicians.

Sarcoma 2017 28;2017:1837475. Epub 2017 Feb 28.

Victorian Adolescent & Young Adult Cancer Service, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Children's Cancer Centre, Royal Children's Hospital, Melbourne, VIC, Australia.

. After treatment, bone sarcoma patients carry a high chance of relapse and late effects from multimodal therapy. We hypothesize that significant variation in surveillance practice exists between pediatric medical oncology (PO) and nonpediatric medical oncology (NP) sarcoma disciplines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/1837475DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5350324PMC
February 2017
9 Reads

Correlation of Ezrin Expression Pattern and Clinical Outcomes in Ewing Sarcoma.

Sarcoma 2017 26;2017:8758623. Epub 2017 Jan 26.

Department of Pediatrics, Emory University, Children's Healthcare of Atlanta, Health Sciences Research Building, Brumley Bridge, 4th Floor, W-470, 1760 Haygood Drive, Atlanta, GA 30322, USA.

. Ezrin is a membrane-cytoskeleton linker protein that has been associated with metastasis and poor outcomes in osteosarcoma and high-grade soft tissue sarcomas. The prognostic value of ezrin expression in Ewing sarcoma is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2017/8758623DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299201PMC
January 2017
17 Reads